Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2022
Event: Initiation of patent infringement litigation.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a legal event.
Material Changes
On March 17, 2022, the Company filed separate lawsuits in the United States District Court for the District of Delaware against:
- Pfizer, Inc. and its subsidiary Pharmacia & Upjohn Co. LLC.
- Moderna, Inc. and its subsidiaries ModernaTX, Inc., and Moderna US, Inc.
The lawsuits allege infringement of U.S. Patent No. 11,246,933 (the "'933 Patent") regarding the manufacture and sale of mRNA COVID-19 vaccines. The patent covers biodegradable cationic lipids foundational to these vaccines.
Guidance, Outlook, and Risks
Relief Sought: The Company is seeking a judgment of infringement and damages adequate to compensate for the infringement. Damages are sought to be no less than a reasonable royalty for unlicensed uses, plus interest and costs.
Injunctive Relief: The Company explicitly stated it is not seeking injunctive relief.
Risks: The outcome of the litigation is uncertain and could result in significant legal costs or potential damages if successful, or dismissal if unsuccessful.
Investor Verification Checklist
- Verify the status and progress of the lawsuits against Pfizer and Moderna in the District of Delaware.
- Review the validity and scope of U.S. Patent No. 11,246,933 regarding biodegradable cationic lipids.
- Monitor future filings for updates on settlement negotiations or court rulings.
- Assess the potential financial impact of reasonable royalty claims on the Company's future revenue streams.